ArticleJournal of hematology & oncology2016

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.

Arnold Bolomsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.